SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-004202
Filing Date
2021-01-07
Accepted
2021-01-07 16:23:30
Documents
12
Period of Report
2021-01-07
Items
Item 2.01: Completion of Acquisition or Disposition of Assets

Document Format Files

Seq Description Document Type Size
1 8-K d40472d8k.htm   iXBRL 8-K 24331
  Complete submission text file 0001193125-21-004202.txt   146333

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA eigr-20210107.xsd EX-101.SCH 3068
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE eigr-20210107_lab.xml EX-101.LAB 18137
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eigr-20210107_pre.xml EX-101.PRE 11406
5 EXTRACTED XBRL INSTANCE DOCUMENT d40472d8k_htm.xml XML 3440
Mailing Address 2155 PARK BOULEVARD PALO ALTO CA 94306
Business Address 2155 PARK BOULEVARD PALO ALTO CA 94306 650-279-9845
Eiger BioPharmaceuticals, Inc. (Filer) CIK: 0001305253 (see all company filings)

IRS No.: 361004130 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36183 | Film No.: 21514448
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences